Detection of von Hippel‐Lindau gene mutation in circulating cell‐free DNA for clear cell renal cell carcinoma

Takayuki Sumiyoshi,Toshinari Yamasaki,Masashi Takeda,Kei Mizuno,Noriaki Utsunomiya,Hiromasa Sakamoto,Eijiro Nakamura,Osamu Ogawa,Shusuke Akamatsu

DOI: https://doi.org/10.1111/cas.14972

IF: 5.7

2021-06-16

Cancer Science

Abstract:<p>The therapeutic landscape of metastatic clear cell renal cell carcinoma (ccRCC) has rapidly expanded, and there is an urgent need to develop non-invasive biomarkers that can select an optimal therapy or evaluate the response in real time. To evaluate the clinical utility of circulating tumor DNA (ctDNA) analysis in ccRCC, we established a highly sensitive assay to detect mutations in von Hippel-Lindau gene (<i>VHL</i>) using a combination of digital PCR and multiplex PCR-based targeted sequencing. The unique assay could detect <i>VHL</i> mutations with a variant allele frequency (VAF) &lt;1.0%. Further, we profiled the mutation status of <i>VHL</i> in 76 cell-free DNA (cfDNA) and 50 tumor tissues from 56 patients with ccRCC using the assay. Thirteen <i>VHL</i> mutations were identified in cfDNA from 12 (21.4%) patients with a median VAF of 0.78% (range, 0.13%–4.20%). Of the 28 patients with <i>VHL</i> mutations in matched tumor tissues, 8 (28.6%) also had <i>VHL</i> mutation in cfDNA with a median VAF of 0.47% (range, 0.13%–2.88%). In serial ctDNA analysis from one patient, we confirmed that VAF of <i>VHL</i> mutation changed consistent with tumor size by radiographic imaging during systemic treatment. In conclusion, <i>VHL</i> mutation in cfDNA was detected only in a small number of patients even using the highly sensitive assay; nevertheless, we showed the potential of ctDNA analysis as a novel biomarker in ccRCC.</p>

oncology